CAMP
Camp4 Therapeutics Corp
$4.47
+1.70%
$228.5M
No data for this timeframe.
Vol
Market Cap$228.5M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders5 funds
Inst. Value$41.0M
Inst. Activity3 buys / 1 sells
SEC Reports2
Press Releases1
Recent Activity
May 14, 2026
SEC
CAMP4 Therapeutics presented new preclinical data for CMP-002, its lead ASO candidate for SYNGAP1-related disorder, at t
8-K — Impact 6/10
May 14, 2026
other
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
<p align="center"><em>CMP-002 administration resulted in a statistically significant improvement in
Apr 23, 2026
SEC
Camp4 Therapeutics Corp filed a Definitive Additional Materials (DEFA14A) for its 2026 annual meeting. The filing is rou
DEFA14A — Impact 2/10
Apr 1, 2026
Insider
Gold Kelly sold 215,000 shares
Chief Financial Officer @ $0.00 ($0.00)
Apr 1, 2026
Insider
MacLean Michael F sold 56,000 shares
Director @ $0.00 ($0.00)
Apr 1, 2026
Insider
Tardiff Daniel sold 170,000 shares
Chief Scientific Officer @ $0.00 ($0.00)
Inst.
FMR LLC — ADD
4,918,243 shares ($30.1M)
Inst.
VANGUARD GROUP INC — DOUBLED
1,672,960 shares ($10.3M)
Price Targets
$8.20
+83.2% upside
Strong Buy
Current $4.48
Low $5.00
Median $8.00
High $12.00
5 analysts
$5.00
$12.00
Analyst Ratings
5Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 14, 2026 | Rodman & Renshaw | INITIATE | Buy |
| Apr 2, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 ▲ +3.3% | $-0.23 — $-0.13 | 68% YoY | 3 |
| Next Q | $-0.18 ▲ +5.4% | $-0.24 — $-0.14 | 67% YoY | 3 |
| Current FY | $-0.77 | $-0.90 — $-0.68 | 53% YoY | 3 |
| Next FY | $-0.73 ▼ -3.5% | $-0.94 — $-0.49 | 5% YoY | 4 |
Latest Reports
BULLISH
8-K
6/10
CAMP4 Therapeutics presented new preclinical data for CMP-002, its lead ASO candidate for SYNGAP1-related disorder, at t
May 14, 2026
NEUTRAL
DEFA14A
2/10
Camp4 Therapeutics Corp filed a Definitive Additional Materials (DEFA14A) for its 2026 annual meeting. The filing is rou
Apr 23, 2026
BULLISH
Press
7/10
CAMP4 Therapeutics reported its 2025 financial results and provided corporate updates, including the advancement of its
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $30.1M | ADD |
| VANGUARD GROUP INC | $10.3M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $579.5K | NEW |
| MORGAN STANLEY | $60.8K | DOUBLED |
| BANK OF AMERICA CORP | $135.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Gold Kelly | A | $0.00 |
| Apr 1, 2026 | MacLean Michael | A | $0.00 |
| Apr 1, 2026 | Tardiff Daniel | A | $0.00 |
| Apr 1, 2026 | Maricich Yuri | A | $0.00 |
| Apr 1, 2026 | Mandel-Brehm Josh | A | $0.00 |
5 institutional holders with $41.0M total value (6,695,670 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, TWO. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 4,918,243 | $30.1M | 73.5% | ADD +62.7% |
| 2 | VANGUARD GROUP INC | 1,672,960 | $10.3M | 25.0% | DOUBLED +433.6% |
| 3 | TWO SIGMA INVESTMENTS, LP | 94,531 | $579.5K | 1.4% | NEW |
| 4 | MORGAN STANLEY | 9,914 | $60.8K | 0.1% | DOUBLED +330366.7% |
| 5 | BANK OF AMERICA CORP /DE/ | 22 | $135.00 | 0.0% | NEAR_EXIT -92.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 3,023,434 | 4,918,243 | +62.7% | $30.1M | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 313,506 | 1,672,960 | +433.6% | $10.3M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 3 | 9,914 | +330366.7% | $60.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 283 | 22 | -92.2% | $135.00 | 2025-Q4 |
| FMR LLC | DOUBLED | 607,946 | 3,023,434 | +397.3% | $9.1M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 97,371 | — | $292.1K | 2025-Q3 |
| UBS Group AG | ADD | 5,088 | 7,043 | +38.4% | $21.1K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 652 | 283 | -56.6% | $849.00 | 2025-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 1,687 | 3 | -99.8% | $9.00 | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 233,833 | 328,891 | +40.7% | $476.9K | 2025-Q2 |
| UBS Group AG | ADD | 3,183 | 5,088 | +59.8% | $7.4K | 2025-Q2 |
| MORGAN STANLEY | NEAR_EXIT | 8,972 | 1,687 | -81.2% | $2.4K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 3,264 | 652 | -80.0% | $946.00 | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 3,781 | 119 | -96.9% | $173.00 | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 16,685 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | TRIM | 14,261 | 8,972 | -37.1% | $35.9K | 2025-Q1 |
| UBS Group AG | TRIM | 10,308 | 3,183 | -69.1% | $12.7K | 2025-Q1 |
| NORGES BANK | EXIT | 35,000 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 200,000 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 200,000 | — | $1.0M | 2024-Q4 |
| NORGES BANK | NEW | — | 35,000 | — | $182.7K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 16,685 | — | $87.1K | 2024-Q4 |
| MORGAN STANLEY | NEW | — | 14,261 | — | $74.4K | 2024-Q4 |
| UBS Group AG | NEW | — | 10,308 | — | $53.8K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | NEW | — | 3,576 | — | $18.7K | 2024-Q4 |
5 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Gold Kelly | Chief Financial Officer | A | 215,000 | $0.00 | $0.00 |
| Apr 1, 2026 | MacLean Michael F | Director | A | 56,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Tardiff Daniel | Chief Scientific Officer | A | 170,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Maricich Yuri | Chief Medical Officer | A | 215,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Mandel-Brehm Josh | Chief Executive Officer | A | 580,000 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 5 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.20 mean target
+83.2% upside
Strong Buy (1.50)
$5.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $4.48 |
| Target Low | $5.00 |
| Target Mean | $8.20 |
| Target Median | $8.00 |
| Target High | $12.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.23 | $-0.13 | 68.3% | +3.3% | 2↑ 0↓ | $0.0B | 20.7% | 3 |
| Next Q 2026-09-30 |
$-0.18 | $-0.24 | $-0.14 | 67.0% | +5.4% | 2↑ 0↓ | $0.0B | 127.3% | 3 |
| Current FY 2026-12-31 |
$-0.77 | $-0.90 | $-0.68 | 53.3% | -0.3% | 1↑ 2↓ | $0.0B | 68.5% | 3 |
| Next FY 2027-12-31 |
$-0.73 | $-0.94 | $-0.49 | 4.8% | -3.5% | 1↑ 2↓ | $0.0B | -10.4% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.197 | |
| 7d ago | $-0.203 | +0.007 |
| 30d ago | $-0.203 | +0.007 |
| 60d ago | $-0.203 | +0.007 |
| 90d ago | $-0.247 | +0.050 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 14, 2026 | Rodman & Renshaw | INITIATE | — | Buy |
| Apr 2, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Jan 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
other
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
<p align="center"><em>CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 hap
May 11, 2026
earnings_calendar
CAMP Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
<p align="center"><em>Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in
Apr 17, 2026
other
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=j3kHZ7b8s6K4WeZ5ZKn4wOG4_4UIMnT9yrJJUIr4
Mar 6, 2026
other
CAMP4 to Participate in Upcoming Investor Conferences
<p align="left">CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=VZXPsXKvec_P2g2J0r-xQJILtHA
Mar 5, 2026
earnings
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
<p align="center"><em>GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as e
Feb 25, 2026
Enforcement
KORENFELD v. CAMP MACHANE, L.L.C.
Court ruling from District Court, D. New Jersey. Docket: 3:25-cv-02329